Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Bill Urges Automatic Insulin Interchangeability

Representative Glenn Grothman Introduces Biosimilar Insulin Access Bill

Executive Summary

A draft Biosimilar Insulin Access Act, intended to waive US interchangeability requirements for FDA-approved biosimilar insulins, has been introduced by representative Glenn Grothman.

You may also be interested in...



Civica Takes First Foray Into Biosimilars With GeneSys Insulins Partnership

Non-profit generics firm Civica is partnering with GeneSys Biologics to make affordable biosimilars of Lantus, Humalog and Novolog for the US market, which it aims to sell at $30 a vial or $55 per pack of cartridges.

Biosimilar Interchangeability: A Blessing Or A Curse?

Biosimilar interchangeability is a hot topic in the US, with the first FDA decision on a formal interchangeability designation expected this month. But across the industry, views differ dramatically on the desirability and likely impact of this additional standard to biosimilarity.

Biosimilar Interchangeability: A Blessing Or A Curse?

Biosimilar interchangeability is a hot topic in the US, with the first FDA decision on a formal interchangeability designation expected this month. But across the industry, views differ dramatically on the desirability and likely impact of this additional standard to biosimilarity.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB150265

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel